The re-emerging concept of personalized healthcare

Personalized Medicine

Volumn 5, Issue 5, 2008, Pages 457-469

  Xu, Li Hui ^a   Zheng, Henry ^a   Sedmark, Daniel D ^a   Sadée, Wolfgang ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

ADR; Adverse drug reaction; BRC1 2; CYP2C9; Genetic testing Her2 NEu; Personalized healthcare; Personalized medicine; Pharmacogenomics; SNP; VKORC1

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; TRASTUZUMAB; WARFARIN;

BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CHRONIC MYELOID LEUKEMIA; CLINICAL GENETICS; COST BENEFIT ANALYSIS; CULTURAL FACTOR; DRUG METABOLISM; GENERAL PRACTICE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC VARIABILITY; GENOMICS; HEALTH CARE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEART INFARCTION; HUMAN; MEDICAL ETHICS; MEDICAL INFORMATICS; MEDICAL SCHOOL; PERSONALIZED HEALTH CARE; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIOECONOMICS; SYSTEMS BIOLOGY; UNSPECIFIED SIDE EFFECT;

EID: 56149103903     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.5.5.457     Document Type: Review

References (27)

1. Poisal JA, Truffer C, Smith S et al.: Health spending projections through 2016: modest changes obscure part D's impact. Health Aff. (Millwood) 26(2). W242-W253 (2007).
2. The World Health Report 2000. WHO, Geneva, Switzerland (2000).
3. Blower PE, Chung JH, Verducci JS et al.: MicroRNAs modulate the chemosensitivity of tumor cells. Mol. Cancer Ther. 7(1), 1-9 (2008).
4. Evans RS, Lloyd JF, Stoddard GJ, Nebeker JR, Samore MH: Risk factors for adverse drug events: a 10-year analysis. Ann. Pharmacother. 39, 1161-1168 (2005).
5. Wadelius, M, Chen LY, Downes K et al.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005).
6. Takahashi, H, Wilkinson GR, Caraco Y et al.: Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin. Pharmacol. Ther. 73, 253-263 (2003).
7. Landefeld, CS, Beyth RJ: Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am. J. Med. 95, 315-328 (1993).
8. Gage B, Eby C, Johnson J, et al.: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. (2008) (Epub ahead of print).
9. Schelleman H, Chen Z, Kealey C et al.: Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin. Pharmacol. Ther. 81(5), 742-747 (207).
10. Rieder MJ, Reiner AP, Gage BF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
11. Higashi MK, Veenstra DL, Kondo LM et al.: Association between CYP2C9 genetic variants and anticoagutation-related outcomes during warfarin therapy, JAMA 287, 1690-1698 (2002).
12. McClain, MR, Palomaki GE, Piper M, Haddow JE: A rapid-ACCE review of CYP2C9 and VKORC1 alieles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet. Med. 10, 89-98 (2008).
13. Landefeld CS, Goldman L: Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am. J. Med. 87, 144-152 (1989).
14. Caraco Y, Blotnick S, Muszkat M: CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized conirolled study. Clin. Pharmacol. Ther. 83, 460-470 (2008).
15. Schwarz UI, Ritchie MD. Bradford Y et al.: Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358. 999-1008 (2008).
16. Bussey HI, Wittkowsky AK, Hylek EM, Walker MB: Genetic testing for warfarin dosing? Not yet ready for prime time. Pharmacotherapy 28(2), 141-143 (2008).
17. Gage BF, Lesko LJ: Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J. Thromb. Thrombolysis 25(1), 45-51 (2008).
18. Shurin SB, Nabel EG: Pharmacogenomics - ready for prime time? N. Engl. J. Med. 358(10), 1061-1063 (2008).
19. Wang D, Chen H. Momary KM, Cavallari LH, Johnson JA, Sadee W: Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 112(4), 1013-1021 (2008).
20. Caldwell MD, Awad T, Johnson A et al.: CYP4F2 genetic variant alters required warfarin dose. Blood 111(8), 4106-4112 (2008).
21. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W: Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286, 2270-2279 (2001).
22. Scata KA, E1-Deiry WS: p53, BRCA1 and breast cancer chemoresistance. Adv Exp. Med. Biol. 608, 70-86 (2007).
23. Dent R, Clemons M: Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence. Cancer Treat. Rev. 32, 144-148 (2006).
24. Druker BJ, Guilhot F, O'Brien SG et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006).
25. Calin GA, Liu CG, Sevignani C et al.: MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl. Acad. Sci. USA 101, 11755-11760 (2004).
26. He H. Jazdzewski K, Li W et al.: The role of microRNA genes in papillary thyroid carcinoma. Proc. Natal. Acad. Sci. USA 102, 19075-19080 (2005).
27. Lu J, Getz G, Miska EA et al.: MicroRNA expression profiles classify human cancers. Nature 435. 834-838 (2005).